Delving into the Latest Updates on Grass pollen allergy immunotherapy(BIAL-Portela & Cia SA) with Synapse

Overview

Basic Info

Drug Type

Allergen extract

Synonyms

Allergenic extract, grass, timothy, Allergenic extract, timothy grass, Allergenic extract,timothy grass pollen

+ [22]

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Immune System DiseasesInfectious DiseasesEye Diseases+ [2]

Active Indication-

Inactive Indication

Allergic rhinoconjunctivitisConjunctivitis, AllergicRhinitis, Allergic, Seasonal

Originator Organization

BIAL-Portela & Cia SA

Active Organization-

Inactive Organization

ROXALL Medizin GmbH

BIAL-Portela & Cia SA

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Login to view timeline

Primary goal of this non-interventional study is to evaluate the change in level of allergen-specific IgE (EAST class) after allergen-specific immunotherapy with Pollinex Quattro with tree and/or grass pollen extracts and their mixtures under medial routine at adults with tree- and/or grass-medicated pollinosis.

Start Date22 Apr 2020

Sponsor / Collaborator

Allergy Therapeutics Plc

NCT02849210

/ CompletedPhase 1

A Phase I Multicenter, Open Clinical Trial With Subcutaneous Immunotherapy in Depot Presentation in Patients With Rhinoconjuncitivis Sensitized to Olea Europaea

The study was designed according to the draft of allergenic product regulation published by Spanish Regulatory Agency. The aim of the study is to evaluate the safety and tolerability of subcutaneous immunotherapy with Olea europaea pollen extract in patients with rhinoconjunctivitis with or without associated mild asthma. In addition, surrogate efficacy parameters will be evaluated: immunoglobulin level changes and skin reactivity

Start Date01 Sep 2015

Sponsor / Collaborator

ROXALL Medicina España S.A.

NCT02477917

/ CompletedPhase 1

A Multicenter, Open Clinical Trial With Subcutaneous Immunotherapy in Depot in Patients With Rhinoconjunctivitis Sensitized to Parietaria Judaica

The study was designed according to the draft of allergenic product regulation published by Spanish Regulatory Agency. The aim of the study is to evaluate the safety and tolerability of subcutaneous immunotherapy with Parietaria judaica pollen extract in patients with rhinoconjunctivitis with or without associated mild asthma. In addition, surrogate efficacy parameters will be evaluated: immunoglobulin level changes and skin reactivity.

Start Date01 May 2015

Sponsor / Collaborator

ROXALL Medicina España S.A.

100 Clinical Results associated with Grass pollen allergy immunotherapy(BIAL-Portela & Cia SA)

Login to view more data

100 Translational Medicine associated with Grass pollen allergy immunotherapy(BIAL-Portela & Cia SA)

Login to view more data

100 Patents (Medical) associated with Grass pollen allergy immunotherapy(BIAL-Portela & Cia SA)

Login to view more data

11

Literatures (Medical) associated with Grass pollen allergy immunotherapy(BIAL-Portela & Cia SA)

01 Dec 2021·Journal of Dairy ScienceQ1 · AGRICULTURAL & FORESTRY SCIENCE

Effects of oral administration of timothy hay and psyllium on the growth performance and fecal microbiota of preweaning calves

Q1 · AGRICULTURAL & FORESTRY SCIENCE

Article

Author: Koike, S ; Hirano, K ; Kodithuwakku, K A H T ; Maruyama, D ; Owada, H ; Miura, H ; Suzuki, Y ; Kobayashi, Y

The objective of this study was to evaluate the effects of oral administration of fiber from the first week of life on the growth and hindgut environment of preweaning calves. Twenty newborn female Holstein calves were divided into 2 groups as control and treatment. Calves in both groups were reared under the same feeding program except for oral fiber administration. Timothy hay and psyllium were mixed at a 50-to-6 ratio as a treatment diet for oral fiber administration. Calves in the treatment group were orally administered 50 g of fiber daily from 3 to 7 d of age and 100 g of fiber from 8 d of age until weaning. Feed intake and occurrence of diarrhea were recorded daily, and body weight (BW) was recorded weekly for the individual calf. Fresh feces were collected from calves at 7, 21, 35, 49, and 56 d of age to analyze fermentation parameters and microbiota to characterize the hindgut environment. Higher fiber intake in the treatment group due to oral administration of timothy and psyllium did not affect the starter intake and achieved higher BW at 21 d of age. The fecal pH, total volatile fatty acid, lactate, and ammonia nitrogen concentrations were not affected by oral fiber administration; meanwhile, the molar proportion of propionate was higher in the treatment group at 7 d of age. The difference in fecal microbiota in the calves subjected to the oral administration of fiber was observed within 21 d of life; Lactobacillus spp. and Prevotella spp. showed higher abundance, whereas that of Clostridium perfringens was decreased. These higher abundances of beneficial bacteria and lower abundance of pathogenic bacteria during early life may partly explain the higher BW of calves in the treatment group at 21 d of age. Furthermore, no adverse effect was observed for the BW and health status in the treatment group throughout the preweaning period. Therefore, early fiber feeding via oral administration potentially contributes to improving the hindgut environment in newborn calves, which leads to better growth of calves during the early stage of life.

01 Apr 2020·The Journal of Allergy and Clinical Immunology: In PracticeQ1 · MEDICINE

Safety of Timothy Grass Sublingual Immunotherapy Tablet in Children: Pooled Analyses of Clinical Trials

Q1 · MEDICINE

Article

Author: Erkka Valovirta ; Michael S. Blaiss ; Veronica Hulstrøm ; Hendrik Nolte ; Graham Roberts ; Susanne Halken

BACKGROUNDTimothy grass sublingual immunotherapy (SLIT) tablets are indicated for children with allergic rhinitis with or without conjunctivitis.OBJECTIVETo use pooled analyses to assess the short- and long-term tolerability and safety of timothy grass SLIT-tablet in children.METHODSData from 9 double-blinded, randomized European or North American trials that included children with allergic rhinitis with or without conjunctivitis treated up to 3 years with once-daily timothy grass SLIT-tablet or placebo were pooled.RESULTSIn all, 1818 (timothy grass SLIT-tablet, n = 923; placebo, n = 895) subjects were included in the analysis. The frequency of treatment-emergent adverse events (AEs) was 86% in the SLIT-tablet group and 83% in the placebo group, and the frequency of treatment-related AEs (TRAEs) was 59% and 23%, respectively. Most (98%) TRAEs were mild to moderate in severity. The 2 most common TRAEs with SLIT-tablet were oral pruritus (33%) and throat irritation (19%), which had a median onset of 1 day and recurrence of 14.5 and 5 days, respectively. In all, 8% of subjects in the SLIT-tablet group and 2% in the placebo group discontinued because of AEs. There were 7 serious AEs assessed as related to SLIT-tablet, 1 systemic allergic reaction (severe with a drop in blood pressure), 3 epinephrine administrations, no eosinophilic esophagitis events, and no serious airway obstructions. The safety profile was similar in subjects across geographic regions and with and without asthma.CONCLUSIONSPooled data indicate that short- and long-term timothy grass SLIT-tablet is well tolerated in children, regardless of geographic region. AEs were generally local, mild, and transient allergic reactions.

01 Aug 2018·AllergyQ1 · MEDICINE

A novel glycocluster molecule prevents timothy‐induced allergic airway inflammation in mice

Q1 · MEDICINE

Article

Author: Lehto, M. ; Leino, R. ; Savolainen, J. ; Wolff, H. ; Alenius, H.

AbstractBackgroundAllergen‐specific immunotherapy (SIT) effectively alleviates type I allergic diseases characterized by T helper (Th)2‐type immunity. Our recent studies have shown that a synthetic trivalent glycocluster, triacedimannose (TADM), suppresses the Th2‐type allergic inflammation. The aim of this study was to compare TADM with two well‐known adjuvants, unmethylated cytosine‐phosphate‐guanine oligodeoxynucleotide (CpG) and monophosphoryl lipid A (MPLA) in a grass allergen‐induced chronic allergic inflammation model in mice.MethodsFemale BALB/c mice were intranasally sensitized with 50 μL of timothy grass pollen extract (TE) twice a week for a period of 15 weeks. Therapeutic intranasal treatments were then performed once a week after the tenth intranasal TE instillation using TADM (10 or 25 μg/50 μL), CpG‐ODN (20 μg/50 μL) or MPLA (2 μg/50 μL). Groups of 9‐10 animals per treatment were killed 24 hours after the last timothy dosage. Blood, bronchoalveolar lavage (BAL) fluids and lung biopsies were taken for subsequent analysis.ResultsWhen mice were repeatedly exposed to TE for 15 weeks, the number of eosinophils and lymphocytes increased in the BAL fluids. The eosinophil and lymphocyte counts decreased dose‐dependently and were practically abolished in the mice treated with TADM. Treatments with MPLA or CpG significantly increased the numbers of neutrophils, while CpG nonsignificantly decreased eosinophilia compared to timothy exposure.ConclusionsA novel synthetic glycocluster molecule inhibited the development of grass‐induced eosinophilic pulmonary inflammation in mice when administrated in the airways. This compound could be a candidate to be used either as an adjuvant in SIT or as a topical anti‐inflammatory treatment.

100 Deals associated with Grass pollen allergy immunotherapy(BIAL-Portela & Cia SA)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB10394

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Rhinitis, Allergic, Seasonal	Phase 2	Germany	ROXALL Medizin GmbH	26 Jan 2021
Allergic rhinoconjunctivitis	Phase 2	Portugal	BIAL-Portela & Cia SA	-
Allergic rhinoconjunctivitis	Phase 2	Portugal	BIAL-Portela & Cia SA	-
Conjunctivitis, Allergic	Phase 2	-	BIAL-Portela & Cia SA	-
Conjunctivitis, Allergic	Phase 2	-	BIAL-Portela & Cia SA	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01567306 (CTgov)	Phase 2	Rhinoconjunctivitis \| Asthma \| Rhinitis, Allergic	151	Allergovac Depot (Allergovac Depot Group 1 Active)	nzdbzuefjk(ptwmdusgjs) = ujdequtjmb qklpfovyhh (ylmkycbhtb, kxvrtztggw - lknjwnvcsn) View more	-	29 Apr 2019
				Allergovac Depot (Allergovac Depot Group 2 Active)	nzdbzuefjk(ptwmdusgjs) = zevgutynnb qklpfovyhh (ylmkycbhtb, tgxmyxoesh - uliyzdvkgg) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data